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Objective: Bipolar disorder places a significant burden on individuals, caregivers and family, and the
broader community. Current treatments are believed to be more effective against manic symptoms,
leaving a shortfall in recovery during the depressive phase of the illness. The current study draws on
recent evidence suggesting that, in addition to increased oxidative load, alterations in mitochondrial
function occur in bipolar disorder.
Methods: This 16-week study aims to explore the potential benefits of N-acetylcysteine (NAC) alone
or in combination (CT) with selected nutraceuticals believed to enhance mitochondrial function. The
study includes adults diagnosed with bipolar disorder currently experiencing an episode of depression.
Participants are asked to take NAC, CT, or placebo in addition to any usual treatments. A post-
discontinuation visit is conducted 4 weeks following the treatment phase.
Results: The primary outcome of the study will be mean change on the Montgomery-Asberg
Depression Rating Scale. Secondary outcomes include functioning, substance use, mania ratings,
and quality of life. Blood samples will be collected at baseline and week 16 to explore biochemical
alterations following treatment.
Conclusion: This study may provide a novel adjunctive treatment for bipolar depression. Analysis of
biological samples may assist in understanding the therapeutic benefits and the underlying etiology of
bipolar depression.
Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12612000830897.
Keywords: Mitochondria; bipolar disorder; depression; acetylcysteine; oxidative stress
Introduction
Given the failure of almost all modern trials of antide-
pressants to demonstrate adequate efficacy in bipolar
disorder (BD) and the limited efficacy of mood stabilizers
(anticonvulsants and atypical antipsychotics) in the
depressive phase of the disorder, the treatment of bipolar
depression is widely acknowledged as the major unmet
need in the disorder. Yet, individuals with BD spend three
times longer in the depressive phase than the manic
phase.1 Together with depressive mixed states, it is the
most lethal phase of the disorder, as it is associated with
substantial suicide risk.2 Bipolar depression is highly
disabling, and causes marked occupational and social
impairment. The three largest and most methodologically
rigorous modern trials of antidepressants in BD (parox-
etine, bupropion, and agomelatine) have all been
negative.3-5
The etiology of BD remains to be fully elucidated.
Therefore, current research is increasingly focusing on
novel pathways. For example, new treatments are being
sought that focus specifically on pathophysiological
aberrations seen in BD. To this end, there is a growing
body of evidence that points to a critical role for oxidative
stress and mitochondrial dysfunction in BD. The aim of
this study is to develop a novel intervention for the
depressive phase of BD which specifically targets
these pathways. In particular, two parallel strategies
will be studied: a definitive exploration of the use of
N-acetylcysteine (NAC), an agent that has robust
antioxidant effects, enhances neurogenesis, reduces
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inflammation, and reverses mitochondrial toxicity; and a
combination of agents that synergistically target mito-
chondrial dysfunction.6,7
Mitochondria are responsible for energy generation,
and are particularly active in oxygen-rich and highly
energy dependent tissues, such as the brain. Impaired
energy metabolism triggers pro-apoptotic signaling, oxi-
dative damage, and excitotoxicity, and impedes mito-
chondrial DNA repair. These processes can interact
and potentiate one another, which, in turn, results in
a continuation of energy depletion. Due to high levels
of oxygen metabolism in brain tissue, mitochondria
are themselves highly susceptible to oxidative stress.8
This then leads to a vicious cycle whereby mitochondrial
dysfunction leads to further oxidative stress, in turn
causing further damage to the mitochondrion. As such,
interventions that improve mitochondrial function by
sustaining adenosine triphosphate (ATP) levels could im-
prove neuronal dysfunction and reduce loss. Importantly,
interventions that buffer intracellular energy levels and
offer neuroprotection may significantly impede the pro-
gression of neurological damage, which is an important
demonstrated feature of BD.9
There is accumulating evidence demonstrating altera-
tions in mitochondrial homeostasis and, subsequently,
function in BD. For example, there is a far higher
prevalence of both BD and depression in people with
mitochondrial disease than in the general population.10
Changes in brain energy levels and markers of energy
metabolism are altered in depression and BD, also
implicating a role of mitochondrial changes in these
illnesses. For example, resting energy expenditure and
maximal aerobic capacity (VO2 max) of individuals during
the manic phase have been shown to be increased when
compared with controls and euthymic participants.11
There is also an established body of data from SPECT
studies showing increased blood flow in mania and
diminished uptake in depression.12 Increased phospho-
monoester and decreased ATP and phosphocreatine
(PCr, a high energy phosphate) levels have been
documented in unmedicated patients with depression.
ATP and PCr appear to normalize following acetyl-L-
carnitine (ALC) treatment, and this correlates with
improvement on Hamilton Depression Rating Scale
(HAM-D) symptom scores.13 Furthermore, Kato et al.14
reported that frontal lobe PCr metabolite levels are
decreased in patients with severe depression.
Subsequent studies suggested that such findings were
also seen in patients with bipolar depression in the left
frontal region, especially in bipolar II disorder,15 and
correlated with HAM-D ratings of depression.16 Further-
more, photic stimulation-induced reduction of PCr in the
occipital cortex was exaggerated in patients with lithium-
resistant BD.17 In addition, there is mounting evidence
showing genetic links between BD and mitochondrial
dysfunction.18-20
The current study has two broad aims. First, we wish
to establish further evidence of the efficacy of NAC in
the management of BD.21,22 As we have previously
reported a significant reduction in depressive symptoms
associated with NAC in people with BD,21-23 a second
positive placebo-controlled trial would provide sufficient
evidence to consider NAC as a first-line therapy. Second,
we aim to develop a combination treatment consisting of
agents with known efficacy in mitochondrial disorders.
We are using a ‘‘systems biology theoretical approach,’’
which suggests that greater efficacy might be attainable
using simultaneous and synergistic combinations of
agents. These agents will be used adjunctively to
augment existing treatments, potentially resulting in
better outcomes for people with BD, specifically those
experiencing the depressive phase of the illness.
We aim to test this using a 16-week treatment trial that
builds on the evidence of mitochondrial dysfunction in BD
and will explore the development of a rational, pathophy-
siologically based intervention for this disorder. This novel
project aims to target underlying mitochondrial dysfunc-
tion in BD with a purpose-designed, multi-component
nutrient formula.
A number of pharmacological treatments and nutri-
tional supplements have previously been used to treat
conventional mitochondrial disorders. These include
antioxidants (ubiquinone, idebenone, vitamin C, vitamin
E, and menadione), agents that specifically improve lactic
acidosis (dichloroacetate and dimethylglycine), agents
that correct secondary biochemical deficiencies (carnitine
and creatine), respiratory chain cofactors (nicotinamide,
thiamine, riboflavin, pantothenic acid, pyridoxine, and
ubiquinone), and hormones (growth hormone and corti-
costeroids).24 While there are few robust findings
(reflecting the nascence of the studies), this literature,
to some extent, informs potential treatment options.
N-acetylcysteine
Robust evidence demonstrates the efficacy of the redox
modulator and glutathione precursor NAC as a treatment
of BD. Our research group conducted the first Stanley
Medical Research Institute-sponsored randomized, pla-
cebo-controlled trials of NAC in both schizophrenia and
BD. In the 6-month schizophrenia trial (n=140), adjunctive
NAC was associated with a significant advantage over
placebo on the Clinical Global Impression (CGI) scale,
the Positive and Negative Symptoms Scale total score,
and the Barnes Akathisia Scale.25 In the 6-month BD trial
(n=75), adjunctive NAC in participants with either BD I or
II disorder was associated with significantly superior
outcomes on the MADRS. Similar findings were evident
on measures of functioning and quality of life, with effect
sizes consistently in the large range on almost all
outcomes measured.23 In both trials, adverse effects did
not significantly differ between the NAC and placebo
groups.
Ubiquinone (coenzyme Q10)
This compound is an endogenous biological chemi-
cal with some evidence for its use in mitochondrial
disorders.8 Ubiquinone links mitochondrial complex I and
III, transferring electrons between the units,26 and
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supplementation may improve the efficiency of this
process. Unpublished pilot data on the use of a pro-
prietary compound containing ubiquinone demonstrated
improvement in mood symptoms in a non-clinical cohort
of a placebo-controlled trial. A number of studies
examining the effects of ubiquinone in mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke
(MELAS) have demonstrated significant reductions in
serum lactate and pyruvate and improvement in brain
ATP synthesis and symptomologies at a dosage of 150
mg/day.27-30 The lack of research examining the potential
benefits of ubiquinone for treatment of BD is surprising.
With evidence of benefits in several other related
pathologies31-33 and its benign tolerability profile, ubiqui-
none appears to be an ideal candidate for further
research in this area.
Alpha-lipoic acid
Alpha-lipoic acid (ALA) is suggested to have antioxidant
properties and play a crucial role in mitochondrial
dehydrogenase reactions. Furthermore, ALA has been
shown to be beneficial in many oxidative stress models,
such as HIV activation, radiation energy, and diabetes
(through inhibition of glycation reactions).34
Acetyl-L-carnitine
ALC is another compound with potential utility in mitochon-
drial disorders. Carnitine is responsible for transport of
fatty acids across the mitochondrial membrane, and plays
a role in energy generation via acetyl-coenzyme A.
Excitotoxicity and disrupted energy metabolism share
free radical-induced oxidative damage as a cause; ALC
has shown potential to correct this.35 The usefulness of
ALC in mood disorders has been suggested by a
treatment trial of 204 patients with dysthymia, where
ALC was equivalent to amisulpride.36 ALC as an adjunct
to psychosocial intervention was reported to be useful in
the treatment of attention deficit/hyperactivity disorder in
63 boys with fragile X syndrome.37 Increased phospho-
monoester and decreased ATP and PCr levels have
been implicated in depression. These levels were
increased and normalized following ALC treatment, and
this increase correlated with trends for improvements in
symptoms based on HAM-D scores in two unmedicated
patients.13 The prevalence of metabolic syndrome in BD
has been described as ‘‘alarmingly high,’’38 and
increased levels of both lactate and glucose are
observed in the cerebrospinal fluid of patients with
BD.39 L-Carnitine has shown some efficacy in glucose
disposal, storage, and uptake in metabolically impaired
and in normal healthy adults.40
Retinyl palmitate (vitamin A equivalent)
Retinal palmitate is a highly bioavailable fat-soluble
compound and is a common form of vitamin A used in
nutraceutical formulas. Vitamin A plays a major role in
physiological processes including vision and reproduction,
in addition to its specific role in cell differentiation and
growth, and, importantly, immune function. Retinol assists
in the modulation of the PKC signaling pathway in
mitochondria. While its antioxidant profile is well estab-
lished, there is also evidence that retinol may be an
electron carrier.41
Vitamin D (cholecalciferol, D3)
Vitamin D is an antioxidant that may be useful in enhancing
mitochondrial function in BD. It plays a predominant role in
the regulation of calcium and phosphate metabolism,42
which may be particularly important, given the alterations
seen in BD. Furthermore, vitamin D is believed to play a
role in the production of melatonin and may be implicated
in seasonal affective disorder.43 Deficiency of vitamin D
has been associated with low mood in a cross-sectional
study of older adults.44 Vitamin D deficiency is prevalent in
psychiatric disorders, and has been linked to the symp-
toms of depression and schizophrenia.45 Furthermore, it
has been reported that the risk of developing psychotic
symptoms is lower in women in the highest quartile of
vitamin D levels, compared with those in the lowest.46
Ascorbic acid (vitamin C)
Ascorbic acid (in the form of calcium ascorbate dihydrate
as used in the current study) has possible efficacy in
mitochondrial myopathy,47 and has a theoretical mechan-
ism of action as an antidepressant in BD through the
suppression of vanadium, which is elevated during manic
episodes.48,49 Ascorbic acid (vitamin C) is also a mediator
in L-carnitine production.50 Dual administration may
strengthen the availability of L-carnitine in addition to its
intrinsic properties.
Tocopherol (vitamin E)
The main function of tocopherol (vitamin E) is to
scavenge free radicals and reduce lipid peroxidation,
which improves mitochondrial membrane integrity.
Studies have suggested that tocopherol and ubiquinone
are more efficient when used together.51 As such,
ascorbic acid and tocopherol could be useful cofactors
in a mitochondrial formulation.
B-group vitamins
Other cofactors associated with improved mitochondrial
function include B vitamins, which often work in synergy,
and thereby are often best administered as a complex.
The water-soluble B vitamins play essential roles in
mitochondrial energy production and cellular function by
a variety of means. Vitamin B1 (thiamine) functions as
a coenzyme in the oxidative decarboxylation of both
pyruvate and alpha-ketoglutarate. The use of thiamine in
the treatment of some forms of pyruvate dehydrogenase
deficiency has been well established.52 This use is
postulated to improve aerobic glycolysis by enhancing
pyruvate decarboxylation. Vitamin B2 (riboflavin) is
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required synergistically with other B vitamins for mito-
chondrial respiration.53 Vitamin B3 (niacin) acts as a
precursor for both nicotinamide adenine dinucleotide
(NAD/NADH) and nicotinamide adenine dinucleotide
phosphate.54 Pantothenic acid (vitamin B5) is required
for the synthesis of coenzyme A, which, among other
roles, is important in the tricarboxylic acid (TCA) cycle. In
a study of immortalized T-cell lines, pantothenic acid was
shown to prevent loss of mitochondrial membrane
potential and also to reestablish ATP synthesis. Levels
of catalase, glutathione peroxidase and glutathione
reductase were also restored following pantothenic acid
treatment.53
Vitamin B6 (pyridoxine) is also involved in mitochon-
drial energy production, and has important effects on
antioxidant status, being involved with aminotransferase
activity.53,55 The major role of NADH is to transfer
electrons from metabolite intermediates to the respiratory
chain. Complex I accepts electrons from NADH and
passes them to ubiquinone. Nicotinamide increases the
cellular NADH and NAD concentration and thereby
enhances substrate availability for complex I.
Vitamin B7 (biotin) is part of the B-group complex
and is responsible for a variety of biological activities,
including promotion of immune and metabolic func-
tion, as well as cellular growth. It is a coenzyme for
five mitochondrial carboxylases and is essential for
growth, development, and normal mitochondrial and
cellular functions, including fatty acid oxidation and
gluconeogenesis.53 Reductions in biotin result in the
loss of mitochondrial complex IV, which leads to
increased production of oxidative species by the
mitochondria.
Vitamin B9 (folic acid) is commonly deficient in
hospitalized psychiatric patients.56 Deficiency in folic
acid impairs synthesis of tetrahydrobiopterin (BH4),
which is essential for the synthesis of serotonin and
other monoamines involved in the pathogenesis of
affective disorders.57 Together with vitamin B12 (in the
form of cyanocobalamin in the current study), folate
plays an essential role in mitochondrial energy pro-
duction through one-carbon transfer pathways.53 B12
is also often deficient in hospitalized psychiatric
patients,58 and works synergistically with folic acid.59
A common finding in vitamin B12 deficiency is perni-
cious anemia, which may cause a derivative secondary
mania.60-62 Even in the absence of clinical features of
pernicious anemia, neurological signs are often present
and, in such cases, may be resolved through B12
supplementation.62-64
Although there are many mitochondrial-enhancing
agents to consider as potential treatments for BD, for
reasons of practicality a number of key agents can be
chosen. Additionally, many mitochondrial agents have
overlapping mechanisms of action as antioxidants. NAC
has been selected as an antioxidant in this trial as it has
the best-established efficacy in mental health, and ALC
and ubiquinone, for their critical roles in mitochondrial
bioenergetics. The cofactor nutrient agents ascorbic
acid, a-tocopherol, thiamine, niacin, folic acid, and
cyanocobalamin were chosen not only because of their
individual benefits, but also due to their synergistic
effects when administered conjunctively with other
mitochondrial agents. Dhitavat et al.65 found a synergis-
tic effect against oxidative stress with combined folic
acid, tocopherol, and carnitine administration, which
provided superior protection against amyloid-beta
induced reactive oxygen species in human neuroblas-
toma cells. In this combination, folic acid was used to
maintain endogenous glutathione, a role provided by
NAC in our combination. Importantly, all agents used in
the present clinical trial are known to have benign
adverse event profiles, with adverse effect rates not
differing significantly from placebo in previous studies.
Finally, the combination has been formulated as not to
interact or deteriorate during storage, allowing maximal
effects from all components.
Methods
Study design
The study is a 16-week, multi-site, randomized, double-
blind, parallel-group trial of a combination therapy (CT),
NAC alone, or placebo in the depressive phase of BD.
Participants receive 16 weeks of daily treatment, adjunc-
tive to treatment as usual, with assessment visits at
baseline, weeks 4, 8, 12, 16, and 20 (washout), and a
phone interview at week 2 (Table 1). Three study sites, in
Geelong, Melbourne, and Sydney, Australia, are recruit-
ing participants. The trial is being conducted in accor-
dance with good clinical practice guidelines, and research
and ethics committee approval was sought before the
start of the study. All components of the active treatment
are well tolerated by humans at the doses proposed for
use in this study and are currently available for purchase
without prescription in Australia.
Trial allocation, sequence generation, and blinding
Pack number allocation to treatment arm is randomly
assigned using permutated block randomization. The
computer-generated randomization plan has been devel-
oped by an independent researcher utilizing four-to-a-
block design. Disposable blister packs containing the trial
medications (Medico Paks) are allocated by trial clinicians
sequentially. Packs are identical so as to conceal
treatment allocation and blinding. To facilitate the
double-blinding process, the trial medications (CT, NAC
only, and placebo) are dispensed by an independent
pharmacist in identical numbers and capsule forms in
sealed containers. The placebo containers are specially
treated with subtherapeutic levels of NAC dust to produce
its characteristic smell (as manufactured in our previous
study). The statistician and trial clinicians are blinded to
group allocation. Participants are assigned randomly and
consecutively to treatment with CT, NAC, or placebo
(1 : 1 : 1 design) in a double-blind fashion. All participants
will remain on treatment as usual (TAU) for the duration of
the trial.
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Treatment regimen
The treatment regimen, including the composition of each
capsule and the agents included in each group, is shown
in Table 2. Each participant is required to take a total of
10 capsules/day (five in the morning and five in the
evening). To clarify the inclusion of ubiquinone and ALC
twice, and the addition of other agents that are not listed
in the rationale above, we are using a commercially
available product (kindly supplied by Bioceuticals). The
manufacturers have provided a product that best fits our
rationale.
As the trial is double-blind, each participant will
consume the same amount of capsules at each dose
time point (twice daily) in all groups. For example, the
NAC-alone group is only required to take four capsules/
day to fulfill the dose of NAC. However, for blinding
purposes, we have included six placebo capsules,
matched to the CT group, to ensure concealment.
Study group
Two hundred and twenty-five participants (aged 18 years
and over) meeting DSM-IV-TR criteria for BD (I, II, or
NOS) on a structured clinical interview (Mini-International
Neuropsychiatric Interview-Plus) with a current acute
depressive episode (MADRS score o 20) will be
recruited. Participants are recruited through their case
clinicians, advertisement, or via private clinicians (e.g.,
family physicians or specialists). Potential participants are
contacted, briefly screened, and a preliminary interview
scheduled. All participants are required to provide written
informed consent before enrollment.
Inclusion criteria
To be included, the participants are required to meet
DSM-IV-TR criteria for BD (I, II, or NOS), have a current
episode of depressive illness with a MADRS score equal
to or greater than 20, have the capacity to consent to the
study and comply with study procedures, and be using
effective contraception if female, sexually active, and of
childbearing age. Participants currently under any form
of therapy for their BD (psychotropic medication or
psychological therapy) are required to have been on a
stable dose of that therapy for at least one month prior
to randomization. Participants are also required to
nominate a current treating physician, and are not
eligible to enter the study until one is identified. If there
is a delay of . 7 days between screening and baseline
assessments, or between baseline assessment and
medication commencement, the MADRS will be admi-
nistered again to ensure the participant still meets
eligibility criteria (. 20).
Table 1 Visit schedule
Visit Visit 1a Visit 1b* Phone call Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Phase Screening Baseline Treatment phase Washout
Week/scale Week 0 Week 0 Week 2 Week 4 Week 8 Week 12 Week 16 Week 20
Informed consent X - - - - - -
MINI-Plus 5.0 X - - - - - -
Concomitant medication X
Entrance criteria X - - - - - -
SAPAS - X
Family history X - - - - -
Psychiatric history X - - - - -
Demographic information X
Habits - X X X X X X
Adverse events - - X X X X X X
Alcohol/substance use - X X X X X X
MADRS with SIGMA X X X X X X X
BDRS - X X X X X X
HAM-A - X X X X X X
YMRS - X X X X X X
LIFE-RIFT - X X X X X X
SOFAS - X X X X X X
Q-LES-Q (short form) - X X X X X X
CGI-BP severity - X X X X X X
CGI-BP Improvement X X X X X
PGI - - X X X X X
Food Frequency Questionnaire - X
Qualitative data collection X X X X X X X X
Adherence to trial medication X X X X X X
Blood sampling (30 ml) - X - - - X -
BDRS = Bipolar Depression Rating Scale; CGI-BP = Clinical Global Impression for Bipolar Disorder; HAM-A = Hamilton Anxiety Rating
Scale; LIFE-RIFT = Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; MADRS = Montgomery-Asberg
Depression Scale; MINI-Plus = Mini-International Neuropsychiatric Interview-Plus; PGI = Patient Global Impression; Q-LES-Q = Quality of
Life Enjoyment and Satisfaction Questionnaire; SAPAS = Standard Assessment of Personality – Abbreviated Scale; SIGMA = Structured
Interview Guide for the Montgomery-Asberg Depression Rating Scale; SOFAS = Social and Occupational Functioning Assessment Scale;
YMRS = Young Mania Rating Scale.
* Screening and baseline visits may be conducted together or as two separate visits, depending on the participant’s needs.
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Exclusion criteria
The following people will be ineligible to take part in the
study: individuals with a known or suspected active
systemic medical disorder, recent gastrointestinal ulcers
or renal stones, individuals who are pregnant or lactating;
individuals who have a diagnosis of epilepsy; those who
are currently taking . 250 mg of NAC, . 250 mg of ALC,
. 25 mg of ubiquinone, or. 200 mg of selenium/day (a 1-
month washout period will be required if participants
currently taking these study preparations would like to
take part); those currently enrolled in any other interven-
tion study; individuals needing warfarin or phenytoin;
individuals who are intolerant to or have had an
anaphylactic reaction to any components of the prepara-
tion; and those with an inability to comply with either the
requirements of informed consent or the treatment
protocol. The exclusion of those on selenium is due to
its antioxidant properties that are mechanistically similar




Withdrawal from the trial occurs if the participants cease
taking their trial medication for 7 consecutive days or if a
participant ceases effective contraception or becomes
pregnant. Dose changes to existing medications (either
increases or decreases in dose) or addition or removal
of an agent are acceptable and participants are allowed
to continue in the trial. Participants are withdrawn from
the study if they withdraw consent or at the discretion of
the investigator in case of adverse events or loss to
follow-up.
Measurements
The participants are assessed at baseline using a
structured clinical interview, the MINI-Plus. A set of
validated outcome measures is completed at baseline
and at weeks 4, 8, 12, 16, and 20. The measures include
the Montgomery Asberg Depression Rating Scale
(MADRS),66 HAM-D,67 Bipolar Depression Rating Scale
(BDRS),68 Young Mania Rating Scale (YMRS),69 CGI’s
Improvement and Severity scales,70 Patient Global
Impression-Improvement subscale, Social and Occupa-
tional Functioning Assessment Scale (SOFAS),71
Longitudinal Interval Follow-up Evaluation – Range of
Impairment Functioning Tool (LIFE RIFT),72 and Quality of
life Enjoyment and Satisfaction Questionnaire (Q-Les-
Q).73 Information on substance use is also gathered. At
week 2, a phone call is made to assess adherence to trial
medication and also to assess any adverse events that
may have occurred. In addition, a modified food frequency
questionnaire, a physical activity questionnaire, and a
Standard Assessment of Personality – Abbreviated Scale
(SAPAS)74 are administered at week 4. Demographic data
are also collected, including, age, weight, height, sex,
psychiatric history and duration of illness.
Table 2 Treatment group composition and dose
Capsule/component Total/capsule Total dose/day Total no. capsules/day
Group 1: combination treatment
Capsule 1: N-acetylcysteine 500 mg 2,000 mg 4
Capsule 2: acetyl-L-carnitine 500 mg 1,000 mg 2
Capsule 3: 2
Ubiquinone (coenzyme Q10) 75 mg* 200 mg
d-alpha-Tocopherol (vitamin E) 3.36 mg (5 IU)* 40.32 mg (60 IU)
Alpha-lipoic acid 75 mg 150 mg
Magnesium (as orotate 500 mg) 32 mg 64 mg
Capsule 4:
Ubidecarenone (coenzyme Q10) 25 mg* 2
d-alpha-Tocopherol (vitamin E) 16.8 mg (25 IU)*
Thiamine hydrochloride 50 mg 100 mg
Riboflavin (vitamin B2) 50 mg 100 mg
Nicotinamide (vitamin B3) 100 mg 200 mg
Calcium pantothenate (equiv. pantothenic acid/vitamin B5) 50 mg (45 mg) 100 mg (90 mg)
Pyridoxine hydrochloride (equiv. pyridoxine/vitamin B6) 50 mg (41.1 mg) 100 mg (82.2 mg)
Folic acid (vitamin B9) 400 mg 800 mg
Cyanocobalamin (vitamin B12) 400 mg 800 mg
Calcium ascorbate dihydrate (equiv. ascorbic acid/vitamin C) 121 mg (100 mg) 242 mg (200 mg)
Retinyl palmitate (equiv. vitamin A) 450 mgRE (1,500 IU) 900 mgRE (3,000 IU)
Cholecalciferol (equiv. 250 IU vitamin D3) 6.25 mg (250 IU) 12.5 mg (500 IU)
Biotin (vitamin H) 300 mg 600 mg
Group 2: N-acetylcysteine group
Capsule 1: N-acetylcysteine 500 mg 2,000 mg 4
Capsules 5, 6, 7: equivalent placebos of Capsules 2, 3, 4 6
Group 3: Placebo group
Capsule 8: equivalent placebo of Capsule 1 4
Capsules 5, 6, 7: equivalent placebos of Capsules 2, 3, 4 6
mgRE = micrograms of retinol equivalent.
* Total dose of ubidecarenone is 200 mg and d-alpha-tocopherol is 40.32 mg (60 IU), combining capsules 4 and 5.
OM Dean et al.
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A purpose-designed qualitative written assessment
will be undertaken to explore the effects of treatment
on participants’ physical and mental health. Clinician
case notes from each visit will be used to explore dif-
ferences over time between the CT, NAC, and placebo
groups.
Adherence is monitored using pill counts of returned
clinical trial material. Adverse events are recorded,
addressed according to medical assessment, and mon-
itored. For consenting participants, blood samples are
collected at baseline and at week 16, to be stored and later
analyzed for serum levels of pyruvate, lactate, and blood
glucose as well as oxidative markers such as cysteine,
glutathione, the lipid peroxidation products malondialde-
hyde and thiobarbituric acid reactive substances, oxidative
enzymes (catalase, superoxide dismutase and glutathione
peroxidase, GSH-Px), polymorphisms of the GSH-Px,
c-glutamylcysteine synthetase, and glutamate cysteine
ligase subunit genes, andmtDNA polymorphisms. Change
in mean MADRS total score is the primary outcome
measure.
Data analysis
Baseline demographic and clinical characteristics will be
examined. Measures of central tendency (mean, median)
and variability (standard deviation, minimum and max-
imum) will be estimated for each continuous measure,
and proportions estimated for categorical variables.
Graphical displays (e.g., histograms and boxplots) will
be produced. Transformations will be used when dis-
tributional assumptions are not fulfilled for inferential
tests. Analysis of the two treatment arms will be
compared to placebo and will first be conducted
independently of the other. This was not designed as a
comparator study to compare the CT and NAC treat-
ments to each other, but rather to explore the benefits of
both treatments independently. Comparisons between
treatment groups will be made as well. The treatment
groups will be compared on baseline demographic and
clinical variables using t-tests or Mann-Whitney U tests
for continuous variables and chi-square tests for catego-
rical variables. If significant baseline group imbalance is
detected on a particular variable and that variable is
correlated with outcome at r . 0.30, then it will be
included as a covariate in the inferential analyses. Each
of the statistical tests above will use a two-tailed alpha
level of 0.05. Mixed-effects linear regression analyses will
compare intervention groups on the repeated assess-
ments of the MADRS over 16 weeks. The mixed-effects
model will include a random intercept and slope over time
and fixed effects for treatment and the stratification
variable site. A treatment by time interaction will be used
to determine if the change in MADRS score varies
between the intervention group over the course of acute
treatment. The treatment by time interaction will be
evaluated using a likelihood ratio test. Analysis of the
qualitative data will use NVivo, with the qualitative
differences between CT and placebo and NAC and
placebo being assessed by blinded researchers. We will
use an operationalized methodology that we have
developed and published.75
Training
All potential raters are required to view the overview
training modules and complete reliability and inter-rater
reliability assessments. All raters are required to conduct
a set of observed interviews on a yearly basis. Any raters
failing to meet stringent certification criteria on an ongoing
basis will be required to undergo additional remedial
training and observation.
Statistical power
Overall power to detect significant differences between
the actual pattern of means will be determined. Assuming
a correlation of post-treatment scores with baseline
measurements of 0.7 and an effect of the dosage such
that the experimental (usual treatment and adjunctive CT)
group differs from controls (usual treatment and placebo)
by 0.75 standard deviation, power will be maintained
above 90% with 75 subjects in each group. Pairwise
comparisons with 75 subjects per group in the three
groups would enable effects smaller than 0.6 standard
deviations to be detected with a power of 80%. These
effect sizes are in the small to moderate range. The
experiment would thus be capable of detecting differ-
ences between groups of clinical and scientific interest
with a total sample size of 225.
Follow-up of adverse events
The research clinician will follow up any participant that
has completed or withdrawn from the study and that has
an ongoing adverse event 30 days after trial medication
has ceased. This is based on recommendations from the
Orygen Youth Health Research Centre Study Services
Unit (internal communication) suggesting that adverse
events should be followed up at a time period which is five
times the half-life of the agent. Based on available
research, cyanocobalamin (vitamin B12) has the longest
half-life of any of the agents in the study (6 days). As
such, any participants who have an ongoing adverse
event at the end of their participation are asked to attend
a final phone call or visit 30 days after project completion/
withdrawal.
If a participant withdraws (or is withdrawn) from the
study early, they are requested to attend a final face-
to-face interview, scheduled to occur as soon as
possible, to capture mood symptoms. If the participant
is experiencing a current adverse event at that time, they
will be asked to be phoned 30 days later to follow up that
event. If the participant does not attend a final face-to-
face visit upon withdrawal, verbal permission will be
sought for a final monitoring phone call (30 days post-
discontinuation).
Participants are instructed that, should they have an
ongoing adverse event that is concerning them following
the completion of the trial, they should contact their
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treating physician rather than wait until the follow-up
phone call 30 days later.
Results
Current data on oxidative stress and mitochondrial
dysfunction in BD, together with the results of previous
trials, present a compelling indication to examine the role
of mitochondrial enhancing agents in BD. To date, we
have randomized 81 participants with a view to complete
the study in early 2015.
Discussion
Bipolar depression remains an unanswered clinical
problem with a progressive and relapsing course.
Recent advancements in the understanding of neurode-
generative process and disease progression of BD have
focused on mitochondrial dysfunction, oxidative stress,
neurotrophic factors, and inflammation76 rather than on
neuroreceptor pathways. Hence, novel treatments are
aiming to modulate oxidative, inflammatory, and neuro-
trophic systems. In particular, attempts to modulate
mitochondrial dysfunction seem promising. The current
RCT follows a ‘‘systems biology theoretical approach’’
and, to our knowledge, will be the first to evaluate the
efficacy of NAC administered alone or with additional
nutraceuticals that target mitochondrial dysfunction in
participants experiencing current bipolar depression. The
advantages of the present study include its double-blind
design, the use of face-to-face clinical interviews rather
than self-reported questionnaires to generate quantitative
and qualitative data, and the inclusion of blood sampling
that would allow searching for correlates of biological
factors.
The study will also contribute to the understanding of
the pathophysiology of bipolar depression. The collection
of blood samples at baseline and at the end of the
treatment phase will allow investigation of relevant
mitochondria-related molecules, as well as those involved
in oxidative stress and inflammation. This will not only
provide an indication of the mechanisms by which these
novel treatments are effective, but might also provide new
targets for development of future therapies.
Most importantly, in contrast to many RCTs, the
present trial uses commercially-available products which
require no additional regulatory approval. Consequently,
participants can continue (or commence, if in the placebo
group) taking active treatment following the completion of
the study. This unique feature is extremely important, as
clinicians could use these agents adjunctively to augment
existing treatments. Moreover, once recruited into the
trial, participants will not be withdrawn even if their
medication (i.e., TAU) is altered, reflecting ‘‘real-life
circumstances.’’
The consensus in the field of BD research is that
the greatest unmet clinical need is bipolar depression.
This study provides a novel therapy to target this phase
of BD specifically. Given that the agents are safe,
affordable, and tolerable, if positive, this study will provide
information with a high impact both clinically and
scientifically.
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